TG Therapeutics says BRIUMVI uptake evenly split

TG Therapeutics says BRIUMVI uptake is evenly split between new, non–CD20 transfer and CD20-switch patients, while CD20 switching stays steady. The company is pursuing an sBLA, ECTRIMS data, pivotal subcutaneous Phase 3 results and other indications with key MS milestones due.